By Wall Street Journal
Thank you for the editorial “Antitrust’s Unholy Grail” (Sept. 7) on the fate of Illumina’s acquisition of Grail, the firm behind the miracle of blood tests that can detect early-occurring cancer cells, enabling early treatment for at least 50 types of cancer.
Previous U.S. presidents announced a war on cancer. President Biden has said much the same. Yet now that Grail has an amazing test, the Federal Trade Commission sees reasons to stop it from getting the help it needs to make its test more widely available. The FTC does…
